

# Benjamin N Rome

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/371431/benjamin-n-rome-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38 papers	1,226 citations	10 h-index	35 g-index
43 ext. papers	1,538 ext. citations	13.5 avg, IF	4.99 L-index

#	Paper	IF	Citations
38	Surgery versus physical therapy for a meniscal tear and osteoarthritis. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1675-84	59.2	368
37	The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2012</b> , 94, 201-7	5.6	330
36	Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 703-11	4.7	208
35	Drug Evaluation during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2282-2284	59.2	101
34	FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 385-91	27.4	47
33	Placing a price on medical device innovation: the example of total knee arthroplasty. <i>PLoS ONE</i> , <b>2013</b> , 8, e62709	3.7	27
32	A comparison of patient-reported and measured range of motion in a cohort of total knee arthroplasty patients. <i>Journal of Arthroplasty</i> , <b>2014</b> , 29, 1378-1382.e1	4.4	20
31	Approval of high-risk medical devices in the US: implications for clinical cardiology. <i>Current Cardiology Reports</i> , <b>2014</b> , 16, 489	4.2	18
30	Medical device innovation--is "better" good enough?. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1464-69	59.2	12
29	Use of "Doctor" Badges for Physician Role Identification During Clinical Training. <i>JAMA Internal Medicine</i> , <b>2019</b> , 179, 1582-1584	11.5	10
28	Estimating Rebates and Other Discounts Received by Medicare Part D. <i>JAMA Health Forum</i> , <b>2021</b> , 2, e210626	10.6	10
27	Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. <i>American Heart Journal</i> , <b>2021</b> , 233, 109-121	4.9	9
26	Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 597-601	11.5	8
25	Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 367-371	6.1	8
24	Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1671-1675	11.6	7
23	Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. <i>Health Affairs</i> , <b>2017</b> , 36, 362-370	7	4
22	US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 1165-1172	11.5	4

21	Drug Prices, Rebates, and Discounts. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 399-405	27.4	4
20	Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1034-1035	10.5	4
19	The Future of Drug-Pricing Transparency. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 489-491	59.2	3
18	Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 995-997	11.5	2
17	Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs. <i>JAMA Network Open</i> , <b>2021</b> , 4, e218816	10.4	2
16	Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. <i>Value in Health</i> , <b>2021</b> , 24, 804-811	3.3	2
15	Sex-Based Role Misidentification and Burnout of Resident Physicians: An Observational Study. <i>Annals of Surgery</i> , <b>2020</b> ,	7.8	1
14	Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020.. <i>JAMA Internal Medicine</i> , <b>2022</b> ,	11.5	1
13	Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2134463	10.4	1
12	Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2135362	10.4	1
11	Medicare Spending on Drugs With Accelerated Approval, 2015-2019. <i>JAMA Health Forum</i> , <b>2021</b> , 2, e213937	10.4	1
10	Frequency Of Generic Drug Price Spikes And Impact On Medicaid Spending. <i>Health Affairs</i> , <b>2021</b> , 40, 779-785	7.85	1
9	Association of California's Prescription Drug Coupon Ban With Generic Drug Use. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 2399-2402	27.4	1
8	Federal Spending on Off-Patent Drugs That Lack Generic Competition. <i>Journal of General Internal Medicine</i> , <b>2021</b> , 36, 821-823	4	1
7	Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1124-1126	11.5	1
6	Raising Medicaid Rebates For Drugs With Accelerated Approval. <i>Health Affairs</i> , <b>2021</b> , 40, 1935-1942	0	1
5	Effect of Shared Electronic Health Records on Duplicate Imaging after Hospital Transfer. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 35, 1617-1619	4	0
4	Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation. <i>Milbank Quarterly</i> , <b>2021</b> , 99, 240-272	3.9	0

- 3 Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling.. *Journal of Clinical Oncology*, **2022**, JCO2102139 2.2
- 2 Reply to Boucher et al. *Clinical Infectious Diseases*, **2021**, 72, e422-e423 11.6
- 1 Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic. *Journal of General Internal Medicine*, **2021**, 36, 3918-3921 4